# A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®

> **NCT05217810** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 600 (estimated)

## Conditions studied

- Asthma

## Interventions

- **OTHER:** Atectura inhalation capsule (150/80ug)
- **OTHER:** Atectura inhalation capsule (150/160ug)
- **OTHER:** Atectura inhalation capsule (150/320ug)

## Key facts

- **NCT ID:** NCT05217810
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-09
- **Primary completion:** 2026-12-23
- **Final completion:** 2026-12-23
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05217810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05217810, "A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05217810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*